title: Clinical significance of CD7-positive stem cell leukemia. A distinct subtype of mixed lineage leukemia.
abstract: Ten leukemia cases with mixed phenotype were investigated in terms of clinical characteristics and cellular origin. Three patients were infants and six patients were older children. Six of them had a high leukocyte count and a mediastinal mass was found in three cases. All but one showed hepatosplenomegaly and/or lymphoadenopathy. In spite of intensive chemotherapy, most of them responded poorly. Cytochemical analysis of their leukemic cells revealed a low percentage of positivity for myeloperoxidase reactivity (less than 25%) in two cases and electron microscopic platelet peroxidase reactivity was found in one of three analyzed cases. Phenotypically, these cells all expressed CD7, and other T-lineage-associated, B-lineage-associated, and/or myeloid-associated antigens were also detected to some extent. In addition, three cases expressed CD41 and one case expressed CD56. The T-cell receptor (TCR) genes and immunoglobulin gene were in the germline configuration in seven cases. In three rearranged cases, two showed only the TCR-delta gene rearrangement, and one had both TCR-gamma and delta gene rearrangements. Cell culture studies with 12-0-tetradecanoyl-phorbol-13-acetate (TPA) revealed differentiation to the T-lineage in two cases and to a myeloid lineage in one case. Megakaryocytic differentiation was detected in two cases in culture without TPA. These results suggest that the cells from these cases arose from stem cells capable of both lymphoid and nonlymphoid differentiation. Although the cells were heterogeneous with regard to their potency of differentiation, they have similar clinical characteristics. Because of poor prognosis, it is important to identify this type of leukemia, and allogenic or autologous bone marrow transplantation should be considered.
authors.affiliation: Department of Pediatrics, Osaka University Hospital, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yumura-Yagi
authors.forename: J
authors.initials: J
authors.lastname: Hara
authors.forename: H
authors.initials: H
authors.lastname: Kurahashi
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: S
authors.initials: S
authors.lastname: Koizumi
authors.forename: Y
authors.initials: Y
authors.lastname: Toyoda
authors.forename: N
authors.initials: N
authors.lastname: Murayama
authors.forename: M
authors.initials: M
authors.lastname: Inoue
authors.forename: S
authors.initials: S
authors.lastname: Ishihara
authors.forename: A
authors.initials: A
authors.lastname: Tawa
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D015703:Antigens, CD / Q000032:analysis*; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D015321:Gene Rearrangement; D005838:Genotype; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007621:Karyotyping; D007938:Leukemia / Q000145:classification* / Q000235:genetics / Q000276:immunology; D008297:Male; D012334:RNA, Neoplasm / Q000032:analysis; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014158:Transcription, Genetic
chemical_list: D015703:Antigens, CD; D019011:Antigens, CD7; D000945:Antigens, Differentiation, T-Lymphocyte; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm; D013755:Tetradecanoylphorbol Acetate